Standardization of molecular monitoring of CML: results and recommendations from the European treatment and outcome study
HE White, M Salmon, F Albano, CSA Andersen… - Leukemia, 2022 - nature.com
Standardized monitoring of BCR:: ABL1 mRNA levels is essential for the management of
chronic myeloid leukemia (CML) patients. From 2016 to 2021 the European Treatment and …
chronic myeloid leukemia (CML) patients. From 2016 to 2021 the European Treatment and …
Development and evaluation of a secondary reference panel for BCR-ABL1 quantification on the International Scale
NCP Cross, HE White, T Ernst, L Welden, C Dietz… - Leukemia, 2016 - nature.com
Molecular monitoring of chronic myeloid leukemia patients using robust BCR-ABL1 tests
standardized to the International Scale (IS) is key to proper disease management, especially …
standardized to the International Scale (IS) is key to proper disease management, especially …
Molecular monitoring of chronic myeloid leukemia: principles and interlaboratory standardization
NCP Cross, A Hochhaus, MC Müller - Annals of hematology, 2015 - Springer
Serial quantification of BCR-ABL1 messenger RNA (mRNA) is an important therapeutic
indicator for patients with chronic myeloid leukemia, but historically, there has been …
indicator for patients with chronic myeloid leukemia, but historically, there has been …
Inter-laboratory comparison of chronic myeloid leukemia minimal residual disease monitoring: summary and recommendations
T Zhang, S Grenier, B Nwachukwu, C Wei… - The Journal of Molecular …, 2007 - Elsevier
In patients with chronic myeloid leukemia, the use of real-time quantitative reverse
transcription-polymerase chain reaction (qRT-PCR) for measuring BCR-ABL1 transcripts …
transcription-polymerase chain reaction (qRT-PCR) for measuring BCR-ABL1 transcripts …
[HTML][HTML] Molecular monitoring of chronic myeloid leukemia: international standardization of BCR-ABL1 quantitation
CJ Zhen, YL Wang - The Journal of Molecular Diagnostics, 2013 - Elsevier
The BCR-ABL1 translocation is a hallmark of chronic myeloid leukemia. Because patients
treated with imatinib and other tyrosine kinase inhibitors achieve lower levels of detectable …
treated with imatinib and other tyrosine kinase inhibitors achieve lower levels of detectable …
Diagnostic performance of the molecular BCR-ABL1 monitoring system may impact on inclusion of CML patients in stopping trials
B Spiess, S Rinaldetti, N Naumann, N Galuschek… - PLoS …, 2019 - journals.plos.org
In chronic myeloid leukemia (CML), the duration of deep molecular response (MR) before
treatment cessation (MR4 or deeper, corresponding to BCR-ABL1≤ 0.01% on the …
treatment cessation (MR4 or deeper, corresponding to BCR-ABL1≤ 0.01% on the …
Standardization of molecular monitoring for chronic myeloid leukemia in Latin America using locally produced secondary cellular calibrators
MS Ruiz, M Medina, I Tapia, J Mordoh, NCP Cross… - Leukemia, 2016 - nature.com
Residual disease in chronic myeloid leukemia (CML) patients undergoing therapy with
tyrosine kinase inhibitors (TKIs) is measured by assessing the quantity of transcripts of the …
tyrosine kinase inhibitors (TKIs) is measured by assessing the quantity of transcripts of the …
Establishment and validation of analytical reference panels for the standardization of quantitative BCR-ABL1 measurements on the international scale
HE White, J Hedges, I Bendit, S Branford… - Clinical …, 2013 - academic.oup.com
BACKGROUND Current guidelines for managing Philadelphia-positive chronic myeloid
leukemia include monitoring the expression of the BCR-ABL1 (breakpoint cluster region/c …
leukemia include monitoring the expression of the BCR-ABL1 (breakpoint cluster region/c …
Performance characteristics of the first Food and Drug Administration (FDA)-cleared digital droplet PCR (ddPCR) assay for BCR::ABL1 monitoring in chronic …
DN Shelton, P Bhagavatula, N Sepulveda, L Beppu… - PLoS …, 2022 - journals.plos.org
Chronic myelogenous leukemia (CML) is a hematopoietic stem cell malignancy that
accounts for 15–20% of all cases of leukemia. CML is caused by a translocation between …
accounts for 15–20% of all cases of leukemia. CML is caused by a translocation between …
Measurement of BCR‐ABL1 by RT‐qPCR in chronic myeloid leukaemia: findings from an International EQA Programme
S Scott, D Travis, L Whitby, J Bainbridge… - British Journal of …, 2017 - Wiley Online Library
Sequential measurement of BCR‐ABL 1 mRNA levels by reverse transcription quantitative
polymerase chain reaction (RT‐qPCR) is embedded in the management of patients with …
polymerase chain reaction (RT‐qPCR) is embedded in the management of patients with …